We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders.
We have two lead clinical-stage product candidates: Keyzilen® (AM-101), which is being developed for the treatment of acute inner ear tinnitus, and AM-111, being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA.
We have additional projects under development and are further strengthening our pipeline through collaborations with leading academic institutions in this field.
AM-125 is being developed for the treatment of vestibular disorders.
In addition, we are pursuing early stage projects for the treatment of tinnitus.